KIYATEC
Kiyatec is a privately held functional precision oncology company that uses patient-derived 3D microtumor assays to predict cancer therapy response, serving neuro-oncologists with its CLIA-certified 3D Predict Glioma clinical test and biopharmaceutical companies with preclinical contract research services.
- Company typePrivate
- Founded2008
- HeadquartersGreenville, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What KIYATEC does
Kiyatec is a privately held functional precision oncology company headquartered in Greenville, South Carolina, that operates a CLIA-certified laboratory and commercializes a proprietary ex vivo 3D cell culture platform. The company's core technology creates up to 1,000 patient-specific microtumors (spheroids) from a patient's live cancer cells and measures their direct response to a panel of chemotherapy agents, generating a functional prediction of therapeutic response in 7-10 days before treatment begins. Its commercial clinical offering is 3D Predict Glioma (CPT Code 0248U), which predicts response to 12 chemotherapy agents in newly diagnosed and recurrent high-grade glioma patients, with published peer-reviewed evidence of 85% prediction accuracy and 5.8-month PFS and 7.6-month OS improvements in test-predicted responders versus nonresponders.
The company's revenue model combines insurance- and Medicare-billed clinical testing for healthcare providers with preclinical contract research services (KIYA-Predict) sold to biopharmaceutical customers such as AstraZeneca and XenoSTART. KIYATEC distributes through direct physician ordering, ships specimen collection kits via UPS Healthcare to its Greenville lab, and returns results through a HIPAA-compliant portal; the test is currently available across most US states except California, New York, and Rhode Island. The company is expanding the platform into additional tumor types — ovarian cancer (2025 launch), NSCLC chemotherapy (2026), and breast cancer (2027) — and in November 2025 received a strategic investment from South Korean firm MBD to integrate automation technology and accelerate US commercial expansion.
KIYATEC is venture-backed, having raised approximately $30-31M cumulatively including an $18M Series C led by Bruker in December 2022, with additional investors including LabCorp, Seae Ventures, VentureSouth, the Brain Tumor Investment Fund, and the Sontag Innovation Fund. The leadership team includes CEO Eric Perreault (formerly of LumiraDx, Lumos Diagnostics, Astute Medical), CSO Tessa DesRochers, PhD, and strategic advisor Mark Capone, former CEO of Myriad Genetics, with co-founder Matt Gevaert, PhD, now serving on the Board.
KIYATEC firmographics
Firmographics- Name
- KIYATEC
- Legal name
- Kiyatec, Inc.
- Website
- https://kiyatec.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kiyatec is a privately held functional precision oncology company that uses patient-derived 3D microtumor assays to predict cancer therapy response, serving neuro-oncologists with its CLIA-certified 3D Predict Glioma clinical test and biopharmaceutical companies with preclinical contract research services.
- Ownership category
- akta.pro rank
KIYATEC industry classification
Industry- Product category
- Functional Precision Oncology Diagnostics
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
Keywords
Where KIYATEC is headquartered
LocationHeadquarters
- HQ city
- Greenville
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
KIYATEC business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Clinical Testing Services: Revenue generated from clinical testing services offered to healthcare providers and patients. The 3D Predict Glioma test is commercially available in the US for high-grade glioma patients. The company bills insurance directly and offers financial assistance for uninsured or underinsured patients.
- Drug Development Services (KIYA-Predict): Preclinical contract testing services for biopharmaceutical companies to assess therapeutic efficacy of investigational drug candidates using 3D spheroid screening platform. Services support preclinical drug development across solid tumor types.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | 3D Predict Glioma test - insurance billed |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
KIYATEC product offering
Product offeringCore offering
KIYATEC operates a proprietary ex vivo 3D cell culture platform that creates up to 1,000 patient-specific microtumors from live cancer cells to predict therapeutic response to chemotherapy before treatment initiation. The company offers the 3D Predict Glioma clinical test (CLIA-certified, CPT 0248U) for newly diagnosed and recurrent high-grade glioma patients screening 12 chemotherapy agents with 7-10 day turnaround, and the KIYA-Predict preclinical service line for biopharmaceutical companies to evaluate investigational oncology drug candidates.
Product overview
KIYATEC is a functional precision oncology company offering a unified platform centered on its proprietary 3D Predict technology. The core 3D Predict Platform uses ex vivo 3D cell culture to create patient-specific microtumors and predict therapeutic response before treatment begins. Commercial offerings include 3D Predict Glioma (CLIA-certified clinical test for high-grade glioma) and KIYA-Predict (preclinical services for biopharmaceutical drug development). The expanding pipeline includes 3D Predict tests for ovarian cancer (2025), non-small cell lung cancer (2026), and breast cancer (2027). The platform delivers results within 7-10 days and has published peer-reviewed evidence correlating predictions to actual patient outcomes.
Differentiator
Problem solved
Functional benefit
Brands
- 3D-Predict: A proprietary ex vivo 3D cell culture technology platform that delivers patient-specific evidence of response to chemotherapy prior to treatment initiation using 3-dimensional spheroids created from patients' live cancer cells.
- KIYA-Predict
- 3D Predict Glioma
Products and services
- 3D Predict Glioma A CLIA-certified clinical test for newly diagnosed and recurrent high-grade glioma patients that predicts therapeutic response to 12 chemotherapy agents including temozolomide, using patient-derived 3D spheroid cultures. Offered to neuro-oncologists, oncologists, and neurosurgeons through direct physician ordering, with results returned within 7-10 days and insurance/Medicare billed directly.
- 3D Predict Platform A proprietary ex vivo 3D cell culture platform that creates up to 1,000 patient-specific microtumors from live cancer cells to predict therapeutic response to cancer treatments before treatment initiation. Underlies Kiyatec's clinical tests and preclinical pharma services.
- KIYA-Predict A preclinical drug development service platform that enables biopharmaceutical companies to assess therapeutic efficacy of investigational drug candidates using patient-derived 3D spheroid screening, supporting clinical candidate selection and translational oncology programs across solid tumor types.
Quantifiable outcome
- 85% accurate prediction of clinical response/nonresponse to temozolomide in newly diagnosed HGG patients (P=0.007)
- +5 more outcomes
Companies that use KIYATEC
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
KIYATEC technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
KIYATEC partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- MBDcoreSouth Korean firm MBD made a strategic investment to accelerate Kiyatec's US commercial expansion. Partnership involves integrating MBD's automation technology into Kiyatec's Greenville, SC laboratory to improve operational efficiency and accelerate launch of diagnostic panels for various cancers.
- XenoSTARTcoreCollaboration to provide correlative ex vivo efficacy data using Kiyatec's 3D spheroid screening platform with XenoSTART's Patient Derived Xenograft (XPDX) models. Partnership helps biopharma rapidly assess efficacy, reduce drug development costs, and expedite the development process.
- AstraZenecacoreMultifaceted research agreement to assess therapeutic efficacy of undisclosed preclinical assets using Kiyatec's KIYA-Predict platform. Agreement aligns with AstraZeneca's strategy of implementing novel oncology solutions with outside partners to develop novel cancer therapeutics.
- NICO CorporationcorePartnership to improve tissue quality for more accurate tumor response prediction. NICO's automated Myriad tissue resection device and Automated Preservation System (APS) collects and biologically preserves tissue in the operating suite, maintaining tumor microenvironment for better predictive accuracy.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
KIYATEC competitors and assessment
Company assessmentBroad incumbents
- Natera: Natera is a molecular diagnostics company with a growing oncology franchise (Signatera MRD, etc.). It is a broader oncology diagnostics incumbent, addressing different clinical questions (MRD, monitoring) than KIYATEC but competing for the same oncology budget and physician relationships.
- Caris Life Sciences: Caris provides molecular profiling (DNA/RNA sequencing and AI-driven biomarker analysis) across oncology and has expanded into therapy selection. It competes for the same oncology diagnostic ordering channel and serves biopharma with companion diagnostic services, overlapping with KIYATEC's clinical and pharma customers.
- Exact Sciences: Exact Sciences is a major molecular diagnostics company (Cologuard, Oncotype DX, etc.) with an expanding oncology portfolio. It is a broad incumbent in cancer diagnostics that competes for oncologist mindshare, though its platform is largely genomic rather than functional.
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) is the established leader in comprehensive genomic profiling of solid tumors. It is a broad incumbent in oncology diagnostics, embedded in NCCN guidelines, and competes with KIYATEC for oncologist ordering behavior — though it focuses on genomic rather than functional testing.
- Tempus Labs: Tempus is a large, multi-modal precision medicine company offering genomic sequencing, AI-driven clinical decision support, and data services across oncology. It is a broader incumbent than KIYATEC — competing for the same oncologist wallet share via molecular profiling — and increasingly adjacent on the functional side through its broader portfolio.
Direct peers
- Champions Oncology: Champions Oncology offers patient-derived xenograft (PDX) models and translational oncology services for both preclinical drug development and clinical decision support. It is highly comparable to KIYATEC's KIYA-Predict business (preclinical efficacy testing) and overlaps with the clinical side via PDX-guided therapy selection.
- SEngine Precision Medicine: SEngine Precision Medicine applies patient-derived 3D tumor cultures and high-throughput drug screening to match cancer patients to effective therapies. It directly parallels KIYATEC's 3D Predict methodology (ex vivo 3D cultures + drug panel testing) and serves the same oncologist/patient segment in functional precision oncology.
- Notable Labs: Notable Labs is a functional precision oncology company that uses patient-derived tumor cells to test drug response ex vivo and predict therapy outcomes. It targets the same clinical use case as KIYATEC's 3D Predict — predicting individual cancer patient response before treatment — making it the closest head-to-head comparable in functional precision medicine.
- Certis Oncology Solutions: Certis Oncology builds patient-derived 3D tumor models and offers preclinical and translational oncology services for biopharma. It mirrors the KIYA-Predict preclinical service offering (functional/3D efficacy testing for pharma) and competes for the same biopharma customers evaluating investigational oncology assets.
Emerging players
- Function Oncology: Function Oncology is an earlier-stage company applying functional genomics and precision oncology approaches to identify patient-specific therapeutic vulnerabilities. It overlaps with KIYATEC's functional precision oncology thesis but is at an earlier stage and uses a different (functional genomics) underlying technology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights7 records
Customer concentration
KIYATEC social profiles
Digital presenceKIYATEC compliance and trust
Trust signalCompliance2 records
KIYATEC financial estimates
Financial estimateRevenue estimate
Valuation estimate
KIYATEC leadership team
Management profileNumber of profiles
Profiles10 records
KIYATEC funding detail
Funding detailFunding overview
Funding rounds14 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
KIYATEC M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about KIYATEC
What does KIYATEC do?
KIYATEC operates a proprietary ex vivo 3D cell culture platform that creates up to 1,000 patient-specific microtumors from live cancer cells to predict therapeutic response to chemotherapy before treatment initiation. The company offers the 3D Predict Glioma clinical test (CLIA-certified, CPT 0248U) for newly diagnosed and recurrent high-grade glioma patients screening 12 chemotherapy agents with 7-10 day turnaround, and the KIYA-Predict preclinical service line for biopharmaceutical companies to evaluate investigational oncology drug candidates.
Is KIYATEC a public or private company?
KIYATEC is a private company. It is classified as venture growth investor backed and is currently operating.
When was KIYATEC founded?
KIYATEC was founded in 2008. It employs 11 to 50 people.
Where is KIYATEC based?
KIYATEC is headquartered in Greenville, United States, in the North America region.
How does KIYATEC make money?
Two revenue lines are on record. Clinical Testing Services are the primary driver. The others are drug Development Services (KIYA-Predict).
Who are KIYATEC's main competitors?
Broad incumbents on record are Natera, Caris Life Sciences, Exact Sciences, Foundation Medicine and Tempus Labs. Direct peers are Champions Oncology, SEngine Precision Medicine, Notable Labs and Certis Oncology Solutions. Function Oncology is listed as an emerging player.
Does KIYATEC have an API?
No public API is recorded for KIYATEC.
What industry is KIYATEC in?
KIYATEC's product category is Functional Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAANAD, Molecular Tumor Boards & Clinical Interpretation Services. Its NAICS code is 621511 and its SIC code is 8071.